Purpose The indicator "concurrent use of three or more psychotropic drugs" has been used as a measure of quality in drug use among the elderly. The aim of our study was to assess to what extent the indicator captures the use of specific psychotropics associated with an increased risk of adverse events among the elderly, i.e., potentially inappropriate psychotropic drugs (PIP). Methods All individuals aged 75 years and older in Sweden purchasing prescribed psychotropic drugs in 2006 constituted the study population (n=384,904). Data on purchased psychotropic drugs from the Swedish Prescribed Drug Register were used. The overlap between individuals with the indicator and individuals using PIP was assessed with sensitivity, specificity, positive and negative predictive values and likelihood ratio as outcome measures. Results Among the psychotropic drug users, 15% had the indicator and 39% used PIP. The proportion of individuals with the indicator among all individuals using PIP was 27% (sensitivity). The proportion of individuals without the indicator among all individuals not using PIP was 93% (specificity). The positive predictive value was 72%, and the negative predictive value was 67%. Differences in outcome measures were observed between different categories of PIP. Conclusions The indicator "concurrent use of three or more psychotropics" can be technically easy to use, but PIP is more specific. Three quarters of all individuals who used PIP in this study were not captured by the indicator.
Introduction
Drug prescribing for the elderly presents challenges due to agerelated changes in body composition and drug elimination, that affect the body's sensitivity to drugs [1] . Consequently, the selection of appropriate drug therapy is complex. Appropriate care should take aspects of risk-benefit assessments, available healthcare resources and patient individuality into account [2] . When this concept is applied to data on drug use only, there is a need to transform and simplify this definition into suitable criteria. Such explicit criteria often focus on pharmacological appropriateness, i.e. choice of drug, dose, drug interactions, duplications and duration of drug therapy, and omit aspects of patients' preferences, comorbidities and underprescribing [3] . These criteria are considered to measure the use of potentially inappropriate drugs.
The development of explicit criteria for measuring the use of potentially inappropriate drugs among the elderly, such as Beers' criteria, has primarily occurred in North America [4] [5] [6] [7] , but also in other countries [8] [9] [10] . The usefulness of such criteria depends on the availability of drugs and prescribing patterns, and they are therefore not easily transferable between countries. A study involving eight European countries found that approximately half of the drugs listed in the criteria originating from North America were not approved for sales in the European countries under study [11] . Further, there were large variations between the European countries.
Quality indicators can be used for assessing the level of quality in healthcare. Measures used as quality indicators should fulfil certain characteristics, such as being measurable, established, relevant, interpretable and subject to being influenced. An indicator should also fulfil basic requirements regarding reliability and validity, including having causal links to relevant health outcomes, such as morbidity or quality of life. The ideal indicator should detect all cases of suboptimal utilization and not classify optimal utilization as suboptimal, i.e. it should have high sensitivity, specificity and predictive values [12] [13] [14] . Indicators should be developed based on the scientific literature or consensus techniques [15] .
Concurrent use of multiple psychotropic drugs, such as a benzodiazepine, a tricyclic antidepressant and a low-dose antipsychotic, has been proposed as an indicator of the inappropriate use of drugs among the elderly [16] . The related indicator "concurrent use of three or more psychotropic drugs" [irrespective of the Anatomical Therapeutic Chemical (ATC) classification system therapeutic subgroup] is included in a proposal of quality indicators and explicit criteria for measuring quality in drug use among the elderly in Sweden [17] . The proposal is based on Swedish recommendations, internationally published explicit criteria and expert opinions. This indicator has been used in several research studies [9, [18] [19] [20] [21] [22] [23] as well as in recent national assessments of quality and efficiency in the Swedish healthcare system [24] . The indicator is considered to be a proxy for polypharmacy (concurrent use of multiple drugs) and to signal poor quality in the treatment of psychiatric disorders. It is also considered to signal an increased risk of adverse outcomes and drug-drug interactions [17] . However, as there are situations when the use of multiple psychotropic drugs is considered appropriate [25] , there is a risk that the indicator may classify appropriate use as poor quality. It is not specified which psychotropics should be included in the combinations for the indicator to measure inappropriate care. An indicator measuring the number of psychotropic drugs used concurrently is thus less informative with respect to the associated risks than measures on specific inappropriate psychotropics. Therefore, the aim of our study was to assess to what extent the indicator "concurrent use of three or more psychotropic drugs" captures the use of specific psychotropics associated with an increased risk of adverse events among the elderly, i.e. potentially inappropriate psychotropic drugs (PIP). A list of such PIP is included in the proposal mentioned earlier (Table 1) [17] .
Methods

Study population
The study population included all individuals aged 75 years and older on 1 January 2006 in Sweden who had purchased at least one prescribed psychotropic drug (ATC codes N05 and N06 [26] ) in a Swedish pharmacy during 2006. The age cut-off of 75 years was chosen since this was the limit used in the national assessment of quality and efficiency in the Swedish healthcare year 2006. The analyses included all prescribed psychotropic drugs purchased by individuals in the study population during the study period.
Data description
Data from the Swedish Prescribed Drug Register were used [27] . The register includes prescribed drugs purchased at all Swedish pharmacies and thereby excludes drugs used in hospitals or purchased over the counter. Information about the patient and the purchased drug (type and amount) is included in the register. Information on prescribers' dosage instructions was available only as a free text section, which is not statistically processable. This dosage information was missing for all prescriptions dispensed as multi-dose packages (ApoDos).
Assessment of prescribed daily doses
The defined daily dose (DDD [26] ) is a technical unit and often lacks clinical relevance when measuring how drugs are used among the elderly. Therefore, a review of prescribed daily doses (PDDs) was conducted in the register. Dosage instructions for a random sample of dispensed prescriptions of all psychotropic substances were performed in the data set. A wide distribution of the patients' sex, age, geographical residence and date of purchase was sought. A PDD was estimated for each reviewed prescription based on drug strength and dosage instruction. Thereafter, a substance-specific population average PDD was estimated. For each substance, values from additional dosage instructions were added until there were no substantial changes in the calculated population average PDD, as judged by the first author. The median number of reviewed instructions per substance was 160 (range 27-295). Midazolam was excluded from the review since the majority of dosage instructions were "according to given instructions". Substances used by fewer than 100 individuals were also excluded from the review (n=18; mean number of users per substance was 32), since the estimations of substance-specific PDDs for these very rare substances would be uncertain and correspond to a negligible impact on results. A theoretical consumption rate of 0.5 DDD/day was assumed for these substances. Substances without assigned DDDs were excluded from the study, since their treatment periods could not be calculated (n=8; each used by fewer than 300 individuals). None of the excluded substances were classified as PIPS.
A similar review for commonly dispensed psychotropic substances was performed for multi-dose users to investigate whether there were substantial differences in PDDs between regular and multi-dose users. This was assessed by the first author. The review was performed in a database at Dosapoteket in Gothenburg, a pharmacy producing multi-dose packages. The database includes information on the prescribed drug, patients' age and sex and dosage instructions.
Definitions of measures
The following definition of concurrent use of three or more psychotropic drugs was used as the standard. At least three different psychotropic drug substances should be concurrently used for at least 40 days, not necessarily consecutive, during the study period. The substances used concurrently were not necessarily the same for all 40 days. The treatment period was assumed to start on the day of purchase, and the theoretical daily drug consumption rate was based on the estimated PDD for each substance according to the review of dosage instructions. The lower limit for number of days of concurrent use was set to be clinically relevant and to exceed temporary short-term treatments, including start packages (≤30 days of treatment).
PIP was defined as the use of potentially inappropriate combinations of psychotropics (PICP) or potentially inappropriate psychotropic substances (PIPS), according to a proposal from the Swedish National Board of Health and Welfare [17] (Table 1 ). The definition of PICP was based on concurrent use of at least two different substances in the specified categories for at least 40 days (not necessarily consecutive or the same substances all 40 days) during the study period. The use of PIPS was defined as at least one purchase during the study period. Alimemazine (ATC R06AD01) and prometazine (ATC R06AD02) are used as hypnotics in clinical practice. These were excluded from the analyses since these are not classified as psychotropics according to the ATC system and would therefore not be identified by the indicator.
Assessment of the indicator
The use of PIP was classified as the reference against which the indicator "concurrent use of three or more psychotropics" was compared. In subanalyses, the indicator was assessed against PICP and PIPS separately. PICP and PIPS were then classified as the references. Sensitivity, specificity, positive and negative predictive values and the likelihood ratio of the indicator were calculated. The sensitivity measures the proportion of individuals with the indicator among all individuals using PIP. The specificity measures the proportion of individuals without the indicator among all individuals not using PIP. The positive predictive value measures the proportion of individuals using PIP among all individuals with the indicator. The negative predictive value measures the proportion of individuals not using PIP among all individuals without the indicator. The likelihood ratio indicates how much more likely the indicator is to be found among individuals using PIP, compared to individuals not using PIP. Data management and the identification of individuals using the indicator and PIP were performed using SAS ver. 9.1 for Windows (SAS Institute, Cary, NC).
Analyses of stability
The theoretical drug consumption rate was altered as follows, using the same rate for all substances: 0.5 DDD/day, 0.75 DDD/day, 1 DDD/day, 1.5 DDD/day, 2 DDD/day. The following required minimum numbers of days of concurrent use were applied: 1, 7, 14, 75 and 120 days. These alterations were compared to the previously defined standard. Limits for days of concurrent use were set to avoid obvious collisions with commonly dispensed amounts. Since the total target population was included, confidence intervals or p values were not calculated around prevalence measures or mean values. The project was approved by the regional ethics board in Gothenburg, Sweden (no. 263-07).
Results
Characteristics of the study population
Among all individuals aged 75 years and older in Sweden in 2006, 384,904 individuals (48%) had purchased at least one psychotropic drug, and were thereby enrolled in the study population. Compared to the whole Swedish population aged 75 years and older, the population of psychotropic drug users were represented by a larger proportion of women (68.7 vs. 60.8%) and a larger proportion of individuals aged 85 years and older (38.9 vs. 29.6%) [28] . The majority of individuals had regularly dispensed drugs only (69.6 vs. 25.7% via multi-dose only). Some individuals (4.7%) shifted during the study period, primarily from regular to multi-dose use. The method used in this study was independent of dispensing type.
Among the different categories of PICP, the use of two or more psychotropics in the same class was most common in the study population of psychotropic drug users (Table 1) . Of all purchased prescriptions during the study period, 16.9% were classified as PIPS. Propiomazine was the most common single PIPS, used by 11.5% of all individuals, while long-acting benzodiazepines as a group were used by 16.8%. The indicator "concurrent use of three or more psychotropics" and use of PICP were more common among individuals with multi-dose dispensed drugs only than among those with regularly dispensed drugs only ( Table 2) .
Assessment of prescribed daily doses
The PDDs estimated for individuals with regularly and multi-dose dispensed drugs were similar. The mean PDD for psychotropic drugs in total was 0.54 DDDs (range 0.1- Assessment of the indicator Figure 1 shows the relation between the indicator and use of PIP, PICP and PIPS in the study population. Among the psychotropic drug users, the sensitivity of the indicator versus PIP was 27%, and the specificity was 93% ( Table 3) . The positive predictive value was 72%, and the negative predictive value was 67%. Individuals using PIP were fourfold more likely to have the indicator compared to individuals not using PIP (likelihood ratio). The sensitivity was higher and the specificity was lower among those with multi-dose dispensed drugs than in those with regularly dispensed drugs. The sensitivity for PICP only as a reference against the indicator was markedly higher than for PIPS only (66 vs. 23%), while the specificity was only slightly higher (92 vs. 90%). Outcome measures varied between the subcategories of PIP.
Analyses of stability
The sensitivity of the indicator decreased with increasing theoretical drug consumption rates and increasing required number of days of concurrent use (Fig. 2) . Although less pronounced, the specificity showed a reversed pattern. Sensitivity and specificity were similar for 1, 7, and 14 days of concurrent use, and the trends became more distinct after the limit of 14 days was passed.
Discussion
The indicator "concurrent use of three or more psychotropics" missed three quarters of the individuals using PIP. Among those individuals with the indicator, two thirds used PIP. Outcome measures varied markedly between the categories of PIP. The indicator captured the use of PICP to a higher extent than the use of PIPS. This may partly be explained by the similar definitions used for the indicator and for PICP. PICP is a measure of combinations of specified psychotropic substances, while the indicator measures any combinations of psychotropic drugs. Furthermore, PICP measures combinations of two or more substances instead of three or more, as measured by the indicator. However, as large differences in results were observed between different categories of PICP, the similarities in definitions would not explain the results as a whole.
The study population only included individuals purchasing psychotropic drugs during the study period; this is in contrast to other studies that used all individuals aged 75 years and older as the study population [23, 24] . The prevalence and specificity of the indicator are affected by whether the study
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Total study population n=384904 Fig. 1 Illustration of the relation between prevalence of any potentially inappropriate psychotropics (PIP, n=150,686), potentially inappropriate combinations of psychotropics (PICP, n=46,742) and potentially inappropriate psychotropic substances (PIPS, n=138,538), respectively, and the indicator "concurrent use of three or more psychotropics" among psychotropic drug users aged 75 years and older in Sweden, in 2006 (n=384,904) population includes psychotropic drug users only or all individuals irrespective of psychotropic drug use. Our study therefore gives a higher prevalence and a lower specificity.
Outcome measures were affected by how the treatment periods were defined. Higher theoretical drug consumption rates and higher limits for number of days of concurrent use yielded lower sensitivities. The changes in specificity were reversed and less pronounced. Both the prevalence of the indicator and of PICP are expected to decrease when the treatment periods are shortened. As PIPS is defined independently of treatment periods, its prevalence is not affected by such changes in definitions, thereby demonstrating the importance of choosing clinically and methodologically relevant definitions when measuring concurrent use of drugs.
Users of multi-dose are a selected population with special needs. Previous studies have found that multi-dose users may be more exposed to potentially inappropriate drug use compared to those using regularly dispensed drugs [29] . Similar findings were observed in the study reported here. The prevalence of the indicator was markedly higher and the use of PIP was slightly more common among those with multi-dose dispensed drugs than among those with regularly dispensed drugs. There were differences in how the indicator captured the use of PIP between the two populations. It is thus important to consider these populations separately.
The indicator is relatively easy to apply in quality assessments as opposed to PIP, which would argue for its use if it is considered an appropriate measure of quality. [30, 31] . However, in some cases, it is possible that drugs classified as potentially inappropriate may have been appropriately prescribed. For instance, tricyclic antidepressants, such as amitriptyline, are sometimes used for neuropathic pain, at doses that are in general lower than those when used as an antidepressant. Antidepressant substances with a more favourable risk-benefit profile, such as selective serotonin reuptake inhibitors, are available [32] , but for neuropathic pain, alternative treatment options are scarce. Nonetheless, drugs are classified as PIP regardless of indication or dosage. The classification of PIP is more informative on the associated risks, while the indicator can be relatively easy to use.
Strengths and limitations
One of the main strengths of our study design was the review of the PDDs conducted before the treatment periods were estimated. As illustrated, there were considerable differences between substances in the ratio between the PDD and the DDD. Thus, a theoretical consumption rate based on one rate for all substances would likely classify treatment periods with less certainty. The concurrent use of drugs can be classified in numerous ways. In order to make the definition of concurrent use manageable in the data analyses, some limitations have to be introduced. The definition did not take into consideration whether or not the days of concurrent use were consecutive, nor did it discriminate between which specific substances were used during the days of concurrent use over the study period. This constraint may have reduced the clinical relevance of the definition.
Conclusion
The indicator "concurrent use of three or more psychotropics" can be technically easy to use, but PIP is more specific. Of all the individuals who used PIP in this study, three quarters were not captured by the indicator. However, two thirds of all individuals with the indicator used PIP. When selecting instruments to assess appropriateness in drug therapy in the elderly, clinical relevance should be balanced against convenience of use.
